The Most Concentrated Hedge Fund Positions Year-to-date - Goldman
Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024
Incyte Stock: Is Wall Street Bullish or Bearish?
Stocks With Three Weeks of Deteriorating Technicals by Piper Sandler
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
Incyte Corporation: Market Successes Counterbalanced by Valuation and Patent Expiry Concerns
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cochlear Limited (OtherCHEOF)
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
Armed With Phase III Win, Incyte Eyes Label Expansion for Monjuvi
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
Sector Update: Health Care Stocks Lean Lower Premarket Friday
Incyte's Niktimvo Faces Market Challenges Despite FDA Approval: Analyst Upholds Hold Rating
Express News | Incyte:Expects to File Supplemental Biologics License Application for Tafasitamab in Combination With Lenalidomide and Rituximab in Fl by End of Year
Express News | Incyte: Phase 3 Inmind Trial Met Its Primary Endpoint
Express News | Incyte Announces Positive Topline Results From Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
Analyst Expectations For Incyte's Future
Moderna Was the Most Shorted S&P 500 Healthcare Stock in July
Incyte Is Maintained at Sector Perform by RBC Capital
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
Incyte Analyst Ratings
No Data